Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine. Labrys' lead candidate, RN-307, is an anti-CGRP monoclonal antibody for the treatment of chronic migraine slated to enter Phase 2 clinical trials in 2013.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/03/13 | $31,000,000 | Series A |
Canaan Partners InterWest Partners Sofinnova Ventures VenBio | undisclosed |
